NIDA's medication development priorities in response to the Opioid Crisis: ten most wanted

Neuropsychopharmacology. 2019 Mar;44(4):657-659. doi: 10.1038/s41386-018-0292-5. Epub 2018 Dec 7.

Authors

Kurt Rasmussen¹, David A White², Jane B Acri²

Affiliations

¹ Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, 6001 Executive Blvd, Bethesda, MD, 20892, USA. kurt.rasmussen@nih.gov.
² Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, 6001 Executive Blvd, Bethesda, MD, 20892, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Drug Development*
Drug Overdose / drug therapy*
Humans
National Institute on Drug Abuse (U.S.)*
Opioid-Related Disorders / drug therapy*
Prescription Drug Misuse
United States